While Ayurveda has traditionally relied on oral, nasal, rectal, and other non-parenteral drug delivery routes, scattered historical texts and 20th-century practices reveal an underexplored tradition of parenteral therapy. This tradition was largely discontinued after the 68th Amendment to the Drugs and Cosmetics Act in 1982 due to concerns over sterility and standardization. However, modern scientific advancements and urgent therapeutic demands have renewed interest in this area. This paper integrates historical, legal, and pharmacological dimensions to propose a roadmap for the safe and scientifically validated revival of Ayurvedic parenteral therapy. We examine recent research, including preclinical studies on polyherbal injectables like Harsha 22, and draw parallels with the successful modernization of Traditional Chinese Medicine (TCM) injections. We also address key challenges such as safety protocols, the erosion of intellectual property rights, and the potential for Ayurvedic formulations to be co-opted under the 'phytopharmaceutical' label, arguing for a new, dedicated regulatory framework to guide this revival.